Inappropriate implantable cardioverter defibrillator discharge following consumption of a dietary weight loss supplement

PACE - Pacing and Clinical Electrophysiology

Volumn 27, Issue 9, 2004, Pages 1317-1320

  McBride, Brian F ^a   Guertin, Danette ^a   White, C Michael ^a   Kluger, Jeffrey ^a,b,c  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Arrhythmia; Complementary medicine; Implantable cardioverter defibrillator; Sudden cardiac death

Indexed keywords

ALPHA TOCOPHEROL; CAFFEINE DERIVATIVE; CHROMIUM PICOLINATE; DAMIANA EXTRACT; ELEUTHEROCOCCUS SENTICOSUS EXTRACT; EPHEDRA EXTRACT; GINGER EXTRACT; GOTU KOLA EXTRACT; MAGNESIUM; METABOLIFE 356; NETTLE EXTRACT; PHOSPHATIDYLCHOLINE; PLANT EXTRACT; POLLEN EXTRACT; ROYAL JELLY; SARSAPARILLA EXTRACT; SOTALOL; SPIRULINA EXTRACT; UNCLASSIFIED DRUG; ZINC;

ADULT; ALTERNATIVE MEDICINE; ARTICLE; ATRIOVENTRICULAR CONDUCTION; CASE REPORT; DEFIBRILLATOR; DIET SUPPLEMENTATION; DOSE RESPONSE; FEMALE; HEART LEFT BUNDLE BRANCH BLOCK; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYDRASTIS EXTRACT; SHOCK; SUPRAVENTRICULAR TACHYCARDIA; WEIGHT REDUCTION;

ADULT; ARRHYTHMIA; DEFIBRILLATORS, IMPLANTABLE; DIETARY SUPPLEMENTS; FEMALE; HUMANS; WEIGHT LOSS;

EID: 4644342534     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2004.00627.x     Document Type: Article

References (14)

1. American Heart Association. 2003 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2002.
2. Antiarrhythmics versus Implantable Defibrillators Investigators. A comparison of antiarrhythmic drug therapy with implantable cardiodefibrillators in patients resuscitated from near fatal ventricular arrhythmias. N Engl Med 1997; 337:1576-1583.
3. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl Med 1996; 335:1933-1940.
4. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl Med 2002; 346:877-883.
5. Data on file. Metabolife International, Inc.
6. Department of Health and Human Services. Dietary supplements containing ephedrine alkaloids. Federal Register. 2000; 65:17510-17511.
7. Hoffman BB, Leftowitz RJ. Catecholamines, sympathetic drugs, and adrenergic receptor antagonists. In JG Hardman, LE Limbird, (eds.): Goodman & Gilman's Pharmacologic Basis of Therapeutics, Ninth Edition. New York, New York, McGraw Hill, 1996, pp. 199-248.
8. Gardner SF, Franks AM, Gurley BJ, et al. Effect of a multicomponent, ephedra-containing dietary supplement (Metabolife 356) on Holter monitoring and hemostatic parameters in healthy volunteers. Am J Cardiol 2003; 91:1510-1513.
9. Mc Bride BF, Karapanos AK, Krudysz A, et al. The electrocardiographic and hemodynamic effects of Metabolife 356(in healthy volunteers. JAMA 2004; (in press).
10. Dilaveris PE, Gialofos EJ, Sideris SK, et al. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 1998; 135:733-738.
11. Zaman AG, Alamgir F, Richens T, et al. The role of signal averaged P-wave duration and serum magnesium as a combined predictor of atrial fibrillation after elective coronary bypass surgery. Heart 1997; 77:527-531.
12. Agency for Healthcare Research and Quality. Ephedra and ephedrine for weight loss and athletic performance enhancement: clinical efficacy and side effects. Washington, DC United States Department of Health and Human Services; 2001.
13. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy ad Safety of ephedra and ephedrine for weight loss and athletic performance: A Meta-Analysis. JAMA 2003; 289:1537-1545.
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharamcol & Ther 1981; 30:239-245.